Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain
Authors:
- Marta Araujo-CastroMarta Araujo-Castro
- Rogelio García-CentenoRGRogelio García-Centeno
- Laura GonzálezLGLaura González
- Felicia A. HanzuFHFelicia A. Hanzu
- Aida OroisAOAida Orois
- Rosa CamaraRCRosa Camara
- María Dolores Ollero GarcíaMGMaría Dolores Ollero García
- Ana Irigaray EcharriAEAna Irigaray Echarri
- Paola Gracia GimenoPGPaola Gracia Gimeno
- Eider Pascual-CorralesEPEider Pascual-Corrales
- Betina BiagettiBBBetina Biagetti
- Andrés CardonaACAndrés Cardona
Open Access
- 25 October 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7575
Abstract
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.Keywords
This publication has 22 references indexed in Scilit:
- Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studiesPituitary, 2025
- Osilodrostat‐induced adrenal insufficiency in a patient with Cushing's diseaseClinical Case Reports, 2022
- Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)Pituitary, 2022
- Consensus on diagnosis and management of Cushing's disease: a guideline updateThe Lancet Diabetes & Endocrinology, 2021
- Epidemiology and mortality of Cushing’s syndromeBest Practice & Research Clinical Endocrinology & Metabolism, 2021
- Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phaseThe Lancet Diabetes & Endocrinology, 2020
- Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysisJournal of Endocrinological Investigation, 2018
- Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysisPituitary, 2018
- Therapeutic Strategies for the Treatment of Severe Cushing’s SyndromeDrugs, 2016
- Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s diseasePituitary, 2015